It’s Time for New Blood in Cancer Medicine

Beth Rogoyski Most would consider a blood test a bit of a pain in the arm, but except for the fantastically needle-phobic, generally not something that would keep you awake at night. Contrast that to the sentiments that spring to mind when you hear the word chemotherapy, and the two couldn’t seem more dissimilar. Despite…

Expanding the network: new connections for an old driver in kidney cancer

Tamara Vital By now you’re probably noticing a running theme at OncoBites: cancer is complicated. Cancers have many moving parts, and despite our best efforts it can be difficult to know what factors drive them. Even when we have identified causal mutations in genes, it can be difficult to figure out how these mutations contribute…

From worms to cures

Emily B. Harrison, Ph.D Last month I attended the first RNA Therapeutics Conference held at University of Massachusetts Medical School. While I have attended several national conferences, this one beautifully encapsulated how basic science can lead to new drugs in only two decades. This conference inspired me to share with you the story of RNA…

New frontiers in breast cancer management

Tamara Vital Over the last several decades, the survival rate for most kinds of breast cancer have increased due to earlier detection, new targeted therapies, and combination treatment modalities. As we’ve discussed before at Oncobites, cancer is not a single disease. It turns out that multiple distinct subtypes exist even within the category of “breast…

The Immune Landscape of Cancer

Morgan McSweeney  Cancer is not a single disease. It is a broad term that describes a number of related conditions in which cells’ growth has begun to bypass the usual checks and balances. To study the spectrum of cancers, the National Institutes of Health have established The Cancer Genome Atlas (TCGA), a collaborative project aimed…